Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia

Blood (2023) 142 (Supplement 1): 78.

https://doi.org/10.1182/blood-2023-181250

Published: 2023

Journal Articles

Comparison of Risk Stratification Tools (ELN-2022, ELN-2017, Lindsley et al. , Papaemmanuil et al. and ALFA classifier) in Predicting Outcomes of Patients with Acute Myeloid Leukemia

Alexandre Iat, Michael Loschi, Sami Benachour, Anne Calleja, Edmond Chiche, Isabelle Sudaka, Danièle Aquaronne, Corinne Ferrero, Patricia Brugel, Lea Ryffel, Laurène Fenwarth, Alice Marceau, Elise Fournier, Berengere Dadone, Thomas Cluzeau

Blood (2022) 140 (Supplement 1): 9105–9106.

https://doi.org/10.1182/blood-2022-164583

Published: 2022

Journal Articles

Negative MRD at Day 100 after Allogenic Hematopoietic Stem Cell Transplant (HSCT): The Grail to Reach in Acute Myeloid Leukemia (AML)

Audrey DA Rocha, Alexis Caulier, Magalie Joris, Amandine Charbonnier, Mathieu Sage, Lavinia Merlusca, Lydia Montes, Nicolas Guillaume, Judith Desoutter, Marie-Noëlle Lacassagne, Marine Quint, Thomas Boyer, Véronique Harrivel, Nicolas Duployez, Alice Marceau, Jean-Pierre Marolleau, Delphine Lebon

Blood (2021) 138 (Supplement 1): 2928.

https://doi.org/10.1182/blood-2021-145523

Published: 2021

Journal Articles

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Blood (2021) 138 (7): 507–519.

https://doi.org/10.1182/blood.2021011103

Published: 2021

Includes: Supplemental data

Journal Articles

Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

Blood (2021) 137 (10): 1424–1428.

https://doi.org/10.1182/blood.2020005756

Published: 2021

Includes: Supplemental data

Journal Articles

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Fleur Cohen Aubart, Damien Roos-Weil, Marine Armand, Alice Marceau-Renaut, Jean-François Emile, Nicolas Duployez, Frédéric Charlotte, Stéphanie Poulain, Raphael Lhote, Zofia Hélias-Rodzewicz, Véronique Della-Valle, Olivier Bernard, Karim Maloum, Florence Nguyen-Khac, Jean Donadieu, Zahir Amoura, Omar Abdel-Wahab, Julien Haroche

Blood (2021) 137 (4): 485–492.

https://doi.org/10.1182/blood.2020005101

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141890

Published: 2020

Journal Articles

MDS/CMML with TET2 or IDH mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation

Lin-Pierre Zhao, MD, Maxime Boy, Celia Azoulay, Emmanuelle Clappier, PhD PharmD, Marie Sébert, MD PhD, Ludivine Amable, Jihene Klibi, Kamel Benlagha, Marion Espeli, Karl Balabanian, Claude Preudhomme, MD PhD, Alice Marceau, Raphael Itzykson, MD PhD, Arsène Mékinian, Olivier Fain, MD, Antoine Toubert, Pierre Fenaux, MD PhD, Nicolas Dulphy, Lionel Ades, MDPhD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141228

Published: 2020

Journal Articles

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Blood (2020) 135 (8): 542–546.

https://doi.org/10.1182/blood.2019003471

Published: 2020

Includes: Supplemental data

Journal Articles

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia

Nicolas Duployez, Christophe Willekens, Isabelle Plo, Alice Marceau-Renaut, Stéphane de Botton, Laurène Fenwarth, Thomas Boyer, Guillemette Huet, Olivier Nibourel, Christian Rose, Brigitte Nelken, Bruno Quesnel, Claude Preudhomme

Blood (2019) 134 (26): 2414–2416.

https://doi.org/10.1182/blood.2019003206

Published: 2019

Includes: Supplemental data

Journal Articles

A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)

Valérie Vidal, Laila Hamri, Alice Marceau-Renaut, Flore Sicre De Fontbrune, MD PhD, Virginie Eclache, Nevine Osman, Benjamin Papoular, Daniel Lusina, Sabine Brechignac, Regis Peffault De Latour, Claude Preudhomme, Claude Gardin, Thorsten Braun, MD PhD

Blood (2018) 132 (Supplement 1): 4007.

https://doi.org/10.1182/blood-2018-99-117237

Published: 2018

Journal Articles

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Blood (2018) 132 (Supplement 1): 993.

https://doi.org/10.1182/blood-2018-99-111144

Published: 2018

Journal Articles

Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms

Edmond Chiche, Sarah Bonnet, Sarah Bertoli, MD PhD, Andrew T Kuykendall, MD, Lauris Gastaud, Pascal Boulay, Veronique De Mas, Eric Delabesse, MD PhD, Alice Marceau-Renaut, Claude Preudhomme, Anne Murati, David A Sallman, MD, S. Dominique Raynaud, MD, Christian Recher, MD PhD, Norbert Vey, MD PhD, Thomas Cluzeau, MD PhD

Blood (2018) 132 (Supplement 1): 2806.

https://doi.org/10.1182/blood-2018-99-114428

Published: 2018

Journal Articles

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia

Raphael Itzykson, Nicolas Duployez, Annette Fasan, Gauthier Decool, Alice Marceau-Renaut, Manja Meggendorfer, Eric Jourdan, Arnaud Petit, Hélène Lapillonne, Jean-Baptiste Micol, Pascale Cornillet-Lefebvre, Norbert Ifrah, Guy Leverger, Hervé Dombret, Nicolas Boissel, Torsten Haferlach, Claude Preudhomme

Blood (2018) 132 (2): 187–196.

https://doi.org/10.1182/blood-2018-03-837781

Published: 2018

Includes: Supplemental data

Journal Articles

Clonal Hematopoiesis in Erdheim-Chester Disease

Julien Haroche, MD PhD, Stéphanie Poulain, MD PhD, Alice Marceau-Renaut, PharmD, Aline Renneville, Catherine Settegrana, Karim Maloum, Damien Roos-Weil, Florence Nguyen-Khac, MD PhD, Jean Donadieu, MD, Jean-François Emile, MD PhD, Zahir Amoura, Fleur Cohen-Aubart, MD PhD

Blood (2017) 130 (Supplement 1): 3788.

https://doi.org/10.1182/blood.V130.Suppl_1.3788.3788

Published: 2017

Journal Articles

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Patients with Acute Myeloid Leukemia with Complex or Micro-Complex Karyotype: Results from the Randomized ALFA-0702 Study

Laurène Fenwarth, MSc, MD, Nicolas Duployez, PharmD, PhD, Xavier Thomas, MD, Nicolas Boissel, MD PhD, Sandrine Geffroy, PhD, Alice Marceau-Renaut, PharmD, Denis Caillot, MD, Emmanuel Raffoux, MD, Emilie Lemasle, MD, Jean-Pierre Marolleau, MD PhD, Céline Berthon, MD PhD, Meyling H. Cheok, MSPharm, PhD, Pauline Peyrouze, Arnaud Pigneux, MD PhD, Norbert Vey, Karine Celli-Lebras, CRA, Christine Terré, PharmD, PhD, Claude Preudhomme, PharmD, PhD, Herve Dombret, MD

Blood (2017) 130 (Supplement 1): 465.

https://doi.org/10.1182/blood.V130.Suppl_1.465.465

Published: 2017

Journal Articles

Molecular Profiling Defines Distinct Prognostic Subgroups in Chilhood Acute Myeloid Leukemia: A Report from the French ELAM02 Study Group

Blood (2017) 130 (Supplement 1): 403.

https://doi.org/10.1182/blood.V130.Suppl_1.403.403

Published: 2017

Journal Articles

Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation

Juliette Lambert, Jérôme Lambert, MDPhD, Xavier Thomas, MD, Alice Marceau-Renaut, PharmD, Aline Renneville, MDPhD, Marie-Magdelaine Coude, MD, Sandrine Hayette, MD, Christian Recher, MD PhD, Emmanuel Raffoux, MD, Arnaud Pigneux, MD PhD, Céline Berthon, MD PhD, Christine Terré, PharmD, PhD, Karine Celli-Lebras, CRA, Sylvie Castaigne, MD, Nicolas Boissel, MD PhD, Philippe Rousselot, Herve Dombret, MD, Claude Preudhomme, PharmD, PhD

Blood (2017) 130 (Supplement 1): 29.

https://doi.org/10.1182/blood.V130.Suppl_1.29.29

Published: 2017

Journal Articles

Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Raphael Itzykson, MD PhD, Nicolas Duployez, PharmD, PhD, Annette Fasan, PhD, Alice Marceau-Renaut, PharmD, Manja Meggendorfer, PhD, Eric Jourdan, MD, Arnaud Petit, MD PhD, Hélène Lapillonne, MD PhD, Jean-Baptiste Micol, MD PhD, Pascale Cornillet-Lefebvre, Norbert Ifrah, MD, Guy Leverger, MD PhD, Herve Dombret, MD, Nicolas Boissel, MD PhD, Torsten Haferlach, MD, Claude Preudhomme, PharmD, PhD

Blood (2017) 130 (Supplement 1): 26.

https://doi.org/10.1182/blood.V130.Suppl_1.26.26

Published: 2017

Journal Articles

Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial

Blood (2016) 128 (22): 1676.

https://doi.org/10.1182/blood.V128.22.1676.1676

Published: 2016

NARROW

Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia

Comparison of Risk Stratification Tools (ELN-2022, ELN-2017, Lindsley et al. , Papaemmanuil et al. and ALFA classifier) in Predicting Outcomes of Patients with Acute Myeloid Leukemia

Negative MRD at Day 100 after Allogenic Hematopoietic Stem Cell Transplant (HSCT): The Grail to Reach in Acute Myeloid Leukemia (AML)

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

MDS/CMML with TET2 or IDH mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia

A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia

Clonal Hematopoiesis in Erdheim-Chester Disease

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Patients with Acute Myeloid Leukemia with Complex or Micro-Complex Karyotype: Results from the Randomized ALFA-0702 Study

Molecular Profiling Defines Distinct Prognostic Subgroups in Chilhood Acute Myeloid Leukemia: A Report from the French ELAM02 Study Group

Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation

Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only